Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocol
Authors:
- A. D. SchachterASA. D. Schachter
- K. E. MeyersKMK. E. Meyers
- L. D. SpaneasLSL. D. Spaneas
- J. A. PalmerJPJ. A. Palmer
- M. SalmanullahMSM. Salmanullah
- J. BaluarteJBJ. Baluarte
- K. L. BraymanKBK. L. Brayman
- W. E. HarmonWHW. E. Harmon
- 26 March 2004
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 8 (2) , 171-177
Abstract
Abstract: Immunosuppression with SRL may provide an opportunity to avoid long‐term exposure to the nephrotoxicity of CNI. Thus, we have initiated an experimental protocol of IL‐2r antibody induction, prednisone, MMF and SRL in pediatric renal transplant recipients (median age 15.5 yr, IQR 8.5, range 1.3–21.7). The recipients were treated with daclizumab every 2 wk for the first 2 months, prednisone on a tapering schedule, MMF at 1200 mg/m2/day and SRL given b.i.d. The SRL was dosed to achieve defined target whole blood 12‐h trough levels. We performed 24 SRL PK profiles in 13 stable pediatric renal transplant recipients at 1 and 3 months post‐transplant. Half‐life (T1/2) and terminal T1/2 were 9.7 (7.1–24.6) and 10.8 (4.4–95.2) hours (median, range) respectively at month 1, and were 9.6 (5–17.8) and 12.1 (4.7–71.0) hours respectively at month 3. SRL trough levels correlated with AUC (r2 = 0.84, p < 0.001). There was no relationship between SRL and mycophenolic acid (MPA) AUC values (r2 = 0.04). During the first 3 months post‐transplant only one patient experienced severe neutropenia and another patient had subclinical (histologic) evidence of a mild acute rejection episode with no change in renal function. We conclude that the T1/2 of SRL in pediatric renal transplant recipients not treated with CNI is much shorter than what has been reported for adults, due to rapid metabolism. We conclude that children require SRL dosing every 12 h, higher doses and frequent drug monitoring to achieve target SRL concentrations.Keywords
This publication has 16 references indexed in Scilit:
- Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis1Pediatric Transplantation, 2004
- Pediatric transplantationAmerican Journal of Transplantation, 2003
- Pharmacodynamics of sirolimus in transplanted children receiving tacrolimusTransplantation Proceedings, 2002
- PROMISING EARLY OUTCOMES WITH A NOVEL, COMPLETE STEROID AVOIDANCE IMMUNOSUPPRESSION PROTOCOL IN PEDIATRIC RENAL TRANSPLANTATION1Transplantation, 2001
- Rejection Profile of Recent Pediatric Renal Transplant Recipients Compared with Historical Controls: a Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)American Journal of Transplantation, 2001
- Impact of developmental pharmacology on pediatric study design: Overcoming the challengesJournal of Allergy and Clinical Immunology, 2000
- Renal Transplantation in ChildrenNew England Journal of Medicine, 1992
- The pediatric nephrologist's dilemma: Growth after renal transplantation and its interaction with age as a possible immunologic variableThe Journal of Pediatrics, 1987
- Impact of Cyclosporine on Renal Transplant Practice at the University of Texas Medical School at HoustonAmerican Journal of Kidney Diseases, 1985
- Use of cyclosporine in pediatric renal transplant recipientsThe Journal of Pediatrics, 1985